- Home
- IONR vs AVIR Comparison
IONR vs AVIR Comparison
Compare IONR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- AVIR
- Stock Information
- Founded
- IONR 2001
- AVIR 2012
- Country
- IONR Australia
- AVIR United States
- Employees
- IONR N/A
- AVIR N/A
- Industry
- IONR
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- IONR
- AVIR Health Care
- Exchange
- IONR Nasdaq
- AVIR Nasdaq
- Market Cap
- IONR 262.0M
- AVIR 273.7M
- IPO Year
- IONR N/A
- AVIR 2020
- Fundamental
- Price
- IONR $3.88
- AVIR $2.85
- Analyst Decision
- IONR
- AVIR Hold
- Analyst Count
- IONR 0
- AVIR 1
- Target Price
- IONR N/A
- AVIR $6.88
- AVG Volume (30 Days)
- IONR 8.3K
- AVIR 247.5K
- Earning Date
- IONR 01-01-0001
- AVIR 03-06-2025
- Dividend Yield
- IONR N/A
- AVIR N/A
- EPS Growth
- IONR N/A
- AVIR N/A
- EPS
- IONR N/A
- AVIR N/A
- Revenue
- IONR N/A
- AVIR N/A
- Revenue This Year
- IONR N/A
- AVIR N/A
- Revenue Next Year
- IONR N/A
- AVIR N/A
- P/E Ratio
- IONR N/A
- AVIR N/A
- Revenue Growth
- IONR N/A
- AVIR N/A
- 52 Week Low
- IONR $3.05
- AVIR $2.75
- 52 Week High
- IONR $9.35
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- IONR 44.78
- AVIR 36.06
- Support Level
- IONR $3.82
- AVIR $2.90
- Resistance Level
- IONR $4.26
- AVIR $3.29
- Average True Range (ATR)
- IONR 0.23
- AVIR 0.12
- MACD
- IONR -0.00
- AVIR -0.03
- Stochastic Oscillator
- IONR 11.97
- AVIR 8.33
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).